ArticleExperimental neurology2016
Chemogenetic silencing of the midline and intralaminar thalamus blocks amygdala-kindled seizures.
Article in Experimental neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 55 citations in OpenAlex.
- Next-generation chemogenetic inhibition using a brain-permeant non-prescription agent.Signal transduction and targeted therapy · 2026Article
- Optogenetic stimulation of the dorsal striatum bidirectionally controls seizures.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Chemogenetic silencing of the subiculum blocks acute chronic temporal lobe epilepsy.Molecular brain · 2024Article
- Recent advances and current status of gene therapy for epilepsy.World journal of pediatrics : WJP · 2024Review
- Chemogenetic Tools and their Use in Studies of Neuropsychiatric Disorders.Physiological research · 2024Review
- Imaging-based chemogenetics for dissecting neural circuits in nonhuman primates.Proceedings of the Japan Academy. Series B, Physical and biological sciences · 2024Review
- Chemogenetic attenuation of cortical seizures in nonhuman primates.Nature communications · 2023Article
- Article
- The intralaminar thalamus: a review of its role as a target in functional neurosurgery.Brain communications · 2023Review
- Grafted hPSC-derived GABA-ergic interneurons regulate seizures and specific cognitive function in temporal lobe epilepsy.NPJ Regenerative medicine · 2022Article
- Pathway-specific inhibition of critical projections from the mediodorsal thalamus to the frontal cortex controls kindled seizures.Progress in neurobiology · 2022Article
- Chemogenetics as a neuromodulatory approach to treating neuropsychiatric diseases and disorders.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Review
- DREADDs in Epilepsy Research: Network-Based Review.Frontiers in molecular neuroscience · 2022Review
- Responsive Thalamic Neurostimulation: A Systematic Review of a Promising Approach for Refractory Epilepsy.Frontiers in human neuroscience · 2022Review
- Distinct Fastigial Output Channels and Their Impact on Temporal Lobe Seizures.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2021Article
- Optogenetic activation of the reticular nucleus of the thalamus attenuates limbic seizures via inhibition of the midline thalamus.Epilepsia · 2021Article
- Chronic loss of inhibition in piriform cortex following brief, daily optogenetic stimulation.Cell reports · 2021Article
- The Subcortical-Allocortical- NeocorticalFrontiers in synaptic neuroscience · 2021Article
- Rostral Intralaminar Thalamus Engagement in Cognition and Behavior.Frontiers in behavioral neuroscience · 2021Review
- Pharmaco-genetic inhibition of pyramidal neurons retards hippocampal kindling-induced epileptogenesis.CNS neuroscience & therapeutics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Temporal lobe epilepsy is the most common form of medically-intractable epilepsy. While seizures in TLE originate in structures such as hippocampus, amygdala, and temporal cortex, they propagate through a crucial relay: the midline/intralaminar thalamus. Prior studies have shown that pharmacological inhibition of midline thalamus attenuates limbic seizures. Here, we examined a recently developed technology, Designer Receptors Exclusively Activated by Designer Drugs (DREADDs), as a means of chemogenetic silencing to attenuate limbic seizures. Adult, male rats were electrically kindled from the amygdala, and injected with virus coding for inhibitory (hM4Di) DREADDs into the midline/intralaminar thalamus. When treated with the otherwise inert ligand Clozapine-N-Oxide (CNO) at doses of 2.5, 5, and 10mg/kg, electrographic and behavioral seizure manifestations were suppressed in comparison to vehicle. At higher doses, we found complete blockade of seizure activity in a subset of subjects. CNO displayed a sharp time-response profile, with significant seizure attenuation seen 20-30min post injection, in comparison to 10 and 40min post injection. Seizures in animals injected with a control vector (i.e., no DREADD) were unaffected by CNO administration. These data underscore the crucial role of the midline/intralaminar thalamus in the propagation of seizures, specifically in the amygdala kindling model, and provide validation of chemogenetic silencing of limbic seizures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.